New Diagnosis? Start Here

News and Stories

RSS

October 17, 2017

To develop new therapies for patients living with myotonic dystrophy (DM), specific infrastructure and information needs to be in place to make clinical trials feasible. The information needed for CDM trials is likely to be different than that used for adult trials.

October 17, 2017

Marsha Dugan likes to describe herself as simply a stay-at-home mom, and avoids talking about her MBA and experience in international business, finance and marketing. Marsha, 60, who stepped back from the business world to raise her two sons, joined the board of the Myotonic Dystrophy Foundation in January 2017.

October 17, 2017

After a year of outreach and education, MDF has successfully convinced the Social Security Administration (SSA) to list congenital myotonic dystrophy (CDM) in its Compassionate Allowances program, significantly easing the application and review process.

September 26, 2017

AMO Pharma released interim results for a Phase 2a safety and toxicity study of Tideglusib (also known as AMO-02) for adolescents and adults with congenital myotonic dystrophy.

September 18, 2017

New data is available on the frequency, progression and treatment of GI symptoms in DM1 and DM2.

September 18, 2017

A new review article assesses the current status of and recommends future directions for brain imaging studies in DM1.

September 18, 2017

Given the brain manifestations of DM1, how aware are most patients of the impact and progression of their disease?

August 15, 2017

Learn more about Dr. Ami Mankodi, principal investigator at the National Institutes of Health’s (NIH) National Institute of Neurological Disorders and Stroke (NINDS) in Bethesda, Maryland. Dr. Mankodi has been involved in research that has helped shape a fundamental biologic and molecular understanding of myotonic dystrophy (DM).

Partners

© Myotonic Dystrophy Foundation. All rights reserved.